• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Global Assessment of Resistance to Neuraminidase Inhibitors: 2008-2011. The Influenza Resistance Information Study (IRIS)

tetano

Editor, Senior Moderator
Clin Infect Dis. 2013 Jan 10. [Epub ahead of print]
Global Assessment of Resistance to Neuraminidase Inhibitors: 2008-2011. The Influenza Resistance Information Study (IRIS).
Whitley RJ, Boucher CA, Lina B, Nguyen-Van-Tam JS, Osterhaus A, Schutten M, Monto AS.
Source

Department of Pediatrics, Microbiology, Medicine and Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Abstract

Background. Following emergence of naturally occurring oseltamivir-resistant A/H1N1 viruses, a global observational investigation, the Influenza Resistance Information Study (IRIS; NCT00884117), was initiated in 2008 to study neuraminidase inhibitor (NAI) resistance and clinical outcome.Methods. Patients with influenza-like illness and/or positive rapid test results agreed to swabs of the posterior nares that were assessed by real-time RT-qPCR for influenza type and subtype and NAI resistance. RT-qPCR-positive specimens were cultured, sequenced and phenotypically tested for NAI resistance. Treatment was at the physician's discretion.Results. Of 1799 influenza-positive (RT-qPCR) patients, 1281 had influenza A (47 seasonal H1N1; 335 H3N2; 899 H1N1pdm2009) and 518 had influenza B. Antivirals were administered to 1041 (58%) patients (26, 245, 514 and 256, respectively). All seasonal H1N1 strains were genotypically (H275Y) and phenotypically resistant to oseltamivir. No genotypic resistance was detected in the Day 1 samples of any other viral subtypes. Mutation-specific (MS) RT-PCR detected resistance to oseltamivir in 19 patients post-baseline (17 H1N1pdm2009 [H275Y]; 2 H3N2 [R292 K]), 14 of whom were children aged ≤5 years. In 12/19 patients, viral loads were too low to permit cell culture and 14/19 were RT-qPCR-negative by Day 10. In one other H1N1pdm2009 patient, H275Y was detected by sequencing but not MS RT-PCR. No emergent resistance was found in influenza B infections.Conclusions. In years 1-3 of IRIS, emergent resistance to oseltamivir in influenza viruses during treatment was uncommon (2.2%) and mostly found in 1-5 year-olds. Viral loads were low in many cases and viral clearance rapid.

PMID:
23307766
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23307766
 
Back
Top Bottom